Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the ...

India: Researchers have discovered in a new study that using a diabetes-specific protein supplement as a partial breakfast replacement improves blood glucose control in people with type 2 diabetes ...

Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical ...

Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the ...

Qnovia, Inc., a pharmaceutical and medtech company revolutionizing inhaled therapeutics, today announced positive results from its Phase 1 clinical trial evaluating the safety and efficacy of ...

As with randomization, if allocation to the study drug is not carried out in accordance with the protocol, the entire study ...

Michael Schmidt Guggenheim Securities, LLC, Research Division. All right. So daraxonrasib, obviously, there's been a lot of focus on the upcoming phase. The first randomized Phase ...

Discusses Share Buyback Program, Financial Position, and Development Strategy for NNZ-2591 February 11, 2026 6:30 ...

Thermo Fisher Scientific, the world leader in serving science, today announced a strategic data collaboration with Datavant, the data collaboration platform trusted for healthcare, to make it easier ...

A randomized crossover weight loss trial in adults with overweight or obesity found that higher protein big breakfasts ...

The recent presentation of the long-term results of the JCOG0802 phase 3 trial has sparked discussion within the international thoracic surgical community. Initial 5-year results in 2022 reported a ...

Background Motor and cognitive dysfunctions are common and disabling features in multiple sclerosis (MS) that remain challenging to treat. Here, we aimed to explore the effect of exergames as a ...